Cloud-Based Bioinformatics for Immune Repertoire Analysis

用于免疫谱分析的基于云的生物信息学

基本信息

  • 批准号:
    8642691
  • 负责人:
  • 金额:
    $ 113.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-08 至 2016-07-22
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Project Title: Cloud-Based Bioinformatics for Immune Repertoire Analysis Organization: GigaGen Inc. PI: David S. Johnson, Ph.D. The Specific Aim of this Phase II SBIR grant application is to launch ClonoByte", a website and cloud-based platform for the processing, storage, analysis, comparison, and visualization of immune signature data sets generated by deep sequencing of immune repertoires. There is a rapidly growing demand for T cell receptor (TCR) and immunoglobulin (Ig) repertoire sequencing as a routine clinical and research practice, but the lack of computational resources and tools is blocking widespread adoption. There is thus a strong additional need for resources to translate immune repertoire data generated by NGS into a format useful to immunology researchers and clinicians. The innovation of our product is to enable researchers with little or no bioinformatics expertise or resources to analyze and interpret immune repertoire sequencing data using a cloud-based platform. In Phase I, we first built individual computational algorithms and components for processing, analysis, and visualization of immune repertoire data, particularly (i) primary processing of sequencing data for V/J gene identification and complementarity-determining region 3 (CDR3) extraction, (ii) calculation of sample oligoclonality and sample-sample similarity, (iii) visualization of comparisons of multiple data sets, and (iv) statistical significance testing of findings via a Monte Carlo method. We tested the computational modules with actual immune repertoire data generated in-house for internal research and for external customers. We then integrated several of the key components into the alpha version of ClonoByte". In Phase II, we will take the following steps to launch ClonoByte": (i) integrate remaining standalone computational modules into ClonoByte" for beta release; (ii) perform software quality control (QC) and quality assurance (QA) and front- end usability testing on ClonoByte" beta; and (iii) refine ClonoByte" beta to launch version. We will be successful if the website can achieve the following in the hands of end-users: (i) securely upload raw immune repertoire sequencing FASTQ files for automated primary processing; (ii) track abundance and expansion of clonotype sequences across multiple annotated data sets; and (iii) compare data sets on the basis of whole- repertoire similarity, sample diversity, and behavior of specific clonotypes. After Phase II, the website will be fully available for commercial use by immune repertoire researchers worldwide. GigaGen's pricing plan will be to offer free use of ClonoByte" for the first 10 samples, and then charge a $50/year subscription fee for users that upload more than 10 samples. Though ClonoByte" will enable analysis of immune repertoire sequencing data generated by most amplification kits or third-party services, GigaGen will use ClonoByte"'s best-in-class features and ease of use to promote its own GigaMune(R) lab services and amplification kits for immune repertoire sequencing.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Scott Johnson其他文献

David Scott Johnson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Scott Johnson', 18)}}的其他基金

Commercialization of an Advanced Technology for T Cell Receptor Analysis and Engineering
T 细胞受体分析和工程先进技术的商业化
  • 批准号:
    9193662
  • 财政年份:
    2016
  • 资助金额:
    $ 113.52万
  • 项目类别:
Recombinant Hyperimmune Gammaglobulin for Primary Immunodeficiency
重组超免疫丙种球蛋白治疗原发性免疫缺陷
  • 批准号:
    9139000
  • 财政年份:
    2016
  • 资助金额:
    $ 113.52万
  • 项目类别:
Recombinant Hyperimmune Gammaglobulin for Primary Immunodeficiency
重组超免疫丙种球蛋白治疗原发性免疫缺陷
  • 批准号:
    9304957
  • 财政年份:
    2016
  • 资助金额:
    $ 113.52万
  • 项目类别:
Production Technology for Recombinant Intravenous Immunoglobulin
重组静脉免疫球蛋白生产技术
  • 批准号:
    8976337
  • 财政年份:
    2015
  • 资助金额:
    $ 113.52万
  • 项目类别:
Recombinant Hyperimmune Gammaglobulin for Pneumococcal Disease
用于治疗肺炎球菌疾病的重组超免疫丙种球蛋白
  • 批准号:
    8979450
  • 财政年份:
    2015
  • 资助金额:
    $ 113.52万
  • 项目类别:
Next-Generation Antibody Discovery and Development Technology
下一代抗体发现和开发技术
  • 批准号:
    9174883
  • 财政年份:
    2014
  • 资助金额:
    $ 113.52万
  • 项目类别:
Therapeutic Antibody Discovery from Pancreatic Cancer B Cell Repertoires
从胰腺癌 B 细胞库中发现治疗性抗体
  • 批准号:
    8832750
  • 财政年份:
    2014
  • 资助金额:
    $ 113.52万
  • 项目类别:
B Cell Repertoire Molecular Platform for Antibody Drug Discovery
用于抗体药物发现的 B 细胞库分子平台
  • 批准号:
    8756836
  • 财政年份:
    2014
  • 资助金额:
    $ 113.52万
  • 项目类别:
Massively Parallel Haplotyping
大规模平行单倍型分析
  • 批准号:
    8198444
  • 财政年份:
    2012
  • 资助金额:
    $ 113.52万
  • 项目类别:
Cloud-Based Analysis of TCR Repertoire Sequencing Data
基于云的 TCR 谱库测序数据分析
  • 批准号:
    8394673
  • 财政年份:
    2012
  • 资助金额:
    $ 113.52万
  • 项目类别:

相似海外基金

WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 113.52万
  • 项目类别:
    Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 113.52万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 113.52万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 113.52万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 113.52万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 113.52万
  • 项目类别:
    EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 113.52万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 113.52万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 113.52万
  • 项目类别:
    Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 113.52万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了